Clinical Trial Update: Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults [Phase 1]

View source ↗

Summary

A Phase 1 safety and pharmacokinetic study evaluated rectal administration of dapivirine gel (0.05%) in HIV-1 seronegative adults; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• dapivirine gel (0.05%) (dapivirine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1 | Status: COMPLETED | Results posted: 2019-11-07